New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GE;DELL;GSK;AZN;BEN;AAPL From The Last 14 Days
Check below for free stories on GE;DELL;GSK;AZN;BEN;AAPL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
July 22, 2014
07:31 EDTAAPLInvestors prepare for large dose of earnings reports
U.S. equity futures are suggesting a market bounce following yesterday’s down day. Investors are feeling optimistic about the week’s large number of earnings reports. Scheduled to release results today are tech heavyweights Apple (AAPL) and Microsoft (MSFT.) Both companies' earnings have the ability to impact the rest of the technology sector. Investors will also be examining the Consumer Prices Index, a housing price index, an existing home sales report, and Richmond Fed manufacturing data.
06:01 EDTAAPLApple asking suppliers to produce 80M large-screen iPhones, WSJ reports
Subscribe for More Information
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
16:00 EDTAAPLOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
14:27 EDTAAPLApple inventory, older iPhone demand should be watched, says BGC Financial
Subscribe for More Information
14:23 EDTAAPLApple July weekly volatility elevated at 57 into Q3
Subscribe for More Information
10:45 EDTAAPLAnalysts roll out coverage on GoPro with differing views
Shares of GoPro (GPRO) are climbing after a number of analysts initiated coverage of the stock with different outlooks. GoPro develops mountable and wearable cameras. BULLISH TAKE: JPMorgan analyst Paul Coster initiated coverage of GoPro with an Overweight rating. GoPro is gaining share in the digital camcorder market, and it has begun to penetrate "active lifestyle" markets, which are a much larger opportunity for the company, Coster believes. The company could ship 10M of its products for use by active lifestyle participants annually, the analyst estimated. In a best case scenario, the company could also sell low-cost devices for the mass market, according to Coster. However, GoPro will face competition from major companies, including Google (GOOG) and possibly Apple (AAPL) in this market, warned Coster, who set a $51 price target on GoPro. Also initiating coverage of the name with an Overweight rating was Piper Jaffray analyst Sean Naughton. GoPro is in the early stages of growth, as the company's user base is poised to expand beyond extreme sports enthusiasts, the analyst forecast. The company has a competitive advantage over other brands, which should enable it to maintain strong profitability, added Naughton, who set a $48 price target on the shares. BEARISH TAKE: Stifel analyst Jim Duffy started coverage of GoPro with a Hold rating. The company's three year growth outlook is compelling, but the stock is fully valued, the analyst believes. The company faces a number of risks, including competition in the image device market and the possibility that its relationship with key channel partners, including Best Buy (BBY), could be disrupted, the analyst wrote. Sales to Best Buy accounted for 17% of GoPro's revenue in fiscal 2013, Duffy reported. After GoPro surged following its initial public offering, the stock is likely to advance by only limited amounts, wrote Barcalys analyst Joseph Wolf, who initiated coverage of the shares with an Equal Weight rating. The stock could fall to $30 if the company is unable to increase its hardware sales or make progress in its efforts to develop a media business, the analyst warned. He set a $45 price target on the shares. PRICE ACTION: A total of seven analysts rolled out coverage today on GoPro, according to The Fly’s research, with only two recommending the stock with buy-equivalent ratings. Shares of the camera marker are up 3%, or $1.10, to $42.53 in morning trading.
10:02 EDTAAPLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:38 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:31 EDTGEGE gas engine technology chosen for power project in Mexico
Subscribe for More Information
09:05 EDTGEGE unit invest $5M in Mebane manufacturing operations
GE’s Industrial Solutions business is investing $5M to strengthen its Mebane North Carolina operations, adding production and testing capabilities that enhance the customer experience. The investment builds on the company’s local footprint that was expanded in October 2013 with the grand opening of GE’s Power Equipment and Power Components global headquarters in Cary, North Carolina. The investment will enable Mebane operations to transition to a dedicated, regional customer experience center where co-located teams will work collaboratively to streamline manufacturing processes and bring new electrical distribution technologies to market. Production of GE’s automatic transfer switches for the data center market is also included in the transition, creating approximately 60 jobs and related growth to the local economy.
08:17 EDTAAPLApple upgraded at JMP Securities
Subscribe for More Information
07:30 EDTGEGeneral Electric annual targets a 'stretch,' says JPMorgan
Subscribe for More Information
07:18 EDTGEAlstom CEO not concerned over complexities added to deal by France, FT says
Subscribe for More Information
07:14 EDTAAPLApple should be owned into tomorrow's results, says Piper Jaffray
Subscribe for More Information
07:11 EDTGSKInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:42 EDTAAPLApple price target raised to $115 from $100 at UBS
Subscribe for More Information
05:57 EDTAAPLApple upgraded to Outperform from Market Perform at JMP Securities
Subscribe for More Information
July 20, 2014
13:06 EDTAAPLFormer Obama spokesman Carney said to consider job at Apple, Bloomberg says
Subscribe for More Information
July 18, 2014
16:47 EDTAAPLMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use